
## Diana M Gibb

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7055484/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mortality after Fluid Bolus in African Children with Severe Infection. New England Journal of Medicine, 2011, 364, 2483-2495.	27.0	1,871
2	Early Antiretroviral Therapy and Mortality among HIV-Infected Infants. New England Journal of Medicine, 2008, 359, 2233-2244.	27.0	1,273
3	Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet, The, 2013, 382, 1555-1563.	13.7	213
4	Exploring mechanisms of excess mortality with early fluid resuscitation: insightsfrom the FEAST trial. BMC Medicine, 2013, 11, 68.	5.5	211
5	Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa. New England Journal of Medicine, 2017, 377, 233-245.	27.0	156
6	Early antiretroviral therapy improves neurodevelopmental outcomes in infants. Aids, 2012, 26, 1685-1690.	2.2	155
7	The impact of antibiotics on growth in children in low and middle income countries: systematic review and meta-analysis of randomised controlled trials. BMJ, The, 2014, 348, g2267-g2267.	6.0	131
8	Undiagnosed HIV Infection among Adolescents Seeking Primary Health Care in Zimbabwe. Clinical Infectious Diseases, 2010, 51, 844-851.	5.8	104
9	A Randomized Trial of Prolonged Co-trimoxazole in HIV-Infected Children in Africa. New England Journal of Medicine, 2014, 370, 41-53.	27.0	101
10	The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis. PLoS Medicine, 2018, 15, e1002514.	8.4	98
11	Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children. New England Journal of Medicine, 2022, 386, 911-922.	27.0	90
12	The expanding role of co-trimoxazole in developing countries. Lancet Infectious Diseases, The, 2015, 15, 327-339.	9.1	87
13	Anaemia and blood transfusion in African children presenting to hospital with severe febrile illness. BMC Medicine, 2015, 13, 21.	5.5	81
14	Neurodevelopment of HIV-exposed uninfected children in South Africa: outcomes from an observational birth cohort study. The Lancet Child and Adolescent Health, 2019, 3, 803-813.	5.6	74
15	Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data. BMJ: British Medical Journal, 1999, 319, 1227-1229.	2.3	73
16	A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. Nature Communications, 2019, 10, 412.	12.8	73
17	Predicting Patterns of Long-Term CD4 Reconstitution in HIV-Infected Children Starting Antiretroviral Therapy in Sub-Saharan Africa: A Cohort-Based Modelling Study. PLoS Medicine, 2013, 10, e1001542.	8.4	71
18	Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and Zimbabwe. Clinical Infectious Diseases, 2012, 55, 1707-1718.	5.8	68

Diana M Gibb

#	Article	IF	CITATIONS
19	Differences in Factors Associated With Initial Growth, CD4, and Viral Load Responses to ART in HIV-Infected Children in Kampala, Uganda, and the United Kingdom/Ireland. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 384-392.	2.1	65
20	Immediate Transfusion in African Children with Uncomplicated Severe Anemia. New England Journal of Medicine, 2019, 381, 407-419.	27.0	64
21	Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation. Science Translational Medicine, 2019, 11, .	12.4	64
22	Predicting mortality in sick African children: the FEAST Paediatric Emergency Triage (PET) Score. BMC Medicine, 2015, 13, 174.	5.5	62
23	Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. Aids, 2007, 21, 77-84.	2.2	59
24	Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia. JAMA - Journal of the American Medical Association, 2021, 326, 1713.	7.4	57
25	Transfusion Volume for Children with Severe Anemia in Africa. New England Journal of Medicine, 2019, 381, 420-431.	27.0	49
26	Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. Lancet Infectious Diseases, The, 2015, 15, 803-809.	9.1	47
27	Survival of HIV-1 vertically infected children. Current Opinion in HIV and AIDS, 2016, 11, 455-464.	3.8	47
28	Transfusion and Treatment of severe anaemia in African children (TRACT): a study protocol for a randomised controlled trial. Trials, 2015, 16, 593.	1.6	42
29	Impact of Cotrimoxazole on Carriage and Antibiotic Resistance of <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> in HIV-Infected Children in Zambia. Antimicrobial Agents and Chemotherapy, 2010, 54, 3756-3762.	3.2	40
30	High Frequency of Blackwater Fever Among Children Presenting to Hospital With Severe Febrile Illnesses in Eastern Uganda. Clinical Infectious Diseases, 2017, 64, 939-946.	5.8	40
31	Growing up with perinatal HIV: changes in clinical outcomes before and after transfer to adult care in the UK. Journal of the International AIDS Society, 2017, 20, 21577.	3.0	36
32	Nevirapine Concentrations in HIV-Infected Children treated with Divided Fixed-Dose Combination Antiretroviral Tablets in Malawi and Zambia. Antiviral Therapy, 2007, 12, 253-260.	1.0	36
33	Review article: directâ€acting antivirals for the treatment of HCV during pregnancy and lactation ― implications for maternal dosing, foetal exposure, and safety for mother and child. Alimentary Pharmacology and Therapeutics, 2019, 50, 738-750.	3.7	35
34	Improved Growth and Anemia in HIV-Infected African Children Taking Cotrimoxazole Prophylaxis. Clinical Infectious Diseases, 2011, 52, 953-956.	5.8	34
35	Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials, 2018, 19, 237.	1.6	33
36	Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children. Antiviral Therapy, 2016, 21, 579-585.	1.0	32

**DIANA M GIBB** 

#	Article	IF	CITATIONS
37	Five year neurodevelopment outcomes of perinatally <scp>HIV</scp> â€infected children on early limited or deferred continuous antiretroviral therapy. Journal of the International AIDS Society, 2018, 21, e25106.	3.0	32
38	TIMING AND INTERPRETATION OF TESTS FOR DIAGNOSING PERINATALLY ACQUIRED HEPATITIS C VIRUS INFECTION. Pediatric Infectious Disease Journal, 2001, 20, 715-716.	2.0	32
39	Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study. PLoS Medicine, 2018, 15, e1002491.	8.4	29
40	Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial. PLoS Medicine, 2018, 15, e1002706.	8.4	28
41	Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial. Lancet HIV,the, 2020, 7, e533-e544.	4.7	28
42	Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations. Clinical Infectious Diseases, 2017, 64, 1597-1603.	5.8	26
43	Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial. Clinical Infectious Diseases, 2018, 66, S140-S146.	5.8	26
44	Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial. Clinical Infectious Diseases, 2018, 66, S132-S139.	5.8	26
45	WHO guidelines on fluid resuscitation in children: missing the FEAST data. BMJ, The, 2014, 348, f7003-f7003.	6.0	25
46	Bacteremia, Causative Agents and Antimicrobial Susceptibility Among HIV-1–infected Children on Antiretroviral Therapy in Uganda and Zimbabwe. Pediatric Infectious Disease Journal, 2013, 32, 856-862.	2.0	24
47	Phase II trial of standard versus increased transfusion volume in Ugandan children with acute severe anemia. BMC Medicine, 2014, 12, 67.	5.5	23
48	Prevalence of Lipodystrophy and Metabolic Abnormalities in HIV-infected African Children after 3 Years on First-line Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2015, 34, e23-e31.	2.0	23
49	Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial. PLoS Medicine, 2017, 14, e1002432.	8.4	22
50	Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial. Lancet HIV,the, 2018, 5, e231-e240.	4.7	22
51	Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration. Lancet HIV,the, 2019, 6, e105-e115.	4.7	22
52	Co-trimoxazole or multivitamin multimineral supplement for post-discharge outcomes after severe anaemia in African children: a randomised controlled trial. The Lancet Global Health, 2019, 7, e1435-e1447.	6.3	21
53	Accuracy of Xpert Ultra in Diagnosis of Pulmonary Tuberculosis among Children in Uganda: a Substudy from the SHINE Trial. Journal of Clinical Microbiology, 2020, 58, .	3.9	20
54	Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy. Journal of Infectious Diseases, 2016, 214, 226-236.	4.0	19

**DIANA M GIBB** 

#	Article	IF	CITATIONS
55	Gastroenteritis aggressive versus slow treatment for rehydration (GASTRO): a phase II rehydration trial for severe dehydration: WHO plan C versus slow rehydration. BMC Medicine, 2019, 17, 122.	5.5	17
56	Rapid antiretroviral therapy initiation in low- and middle-income countries: A resource-based approach. PLoS Medicine, 2019, 16, e1002723.	8.4	16
57	Transfusion management of severe anaemia in African children: a consensus algorithm. British Journal of Haematology, 2021, 193, 1247-1259.	2.5	15
58	Haematological quality and age of donor blood issued for paediatric transfusion to four hospitals in subâ€6aharan Africa. Vox Sanguinis, 2019, 114, 340-348.	1.5	13
59	Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Lancet HIV,the, 2022, 9, e341-e352.	4.7	12
60	Transient Viral Load Increases in HIV-Infected Children in the UK and Ireland: What do They Mean?. Antiviral Therapy, 2007, 12, 949-956.	1.0	12
61	Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled Trial (CAP-IT). BMJ Open, 2019, 9, e029875.	1.9	10
62	HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 42-53.	2.1	9
63	Incidence and predictors of hospital readmission in children presenting with severe anaemia in Uganda and Malawi: a secondary analysis of TRACT trial data. BMC Public Health, 2021, 21, 1480.	2.9	9
64	Sickle cell anaemia and severe Plasmodium falciparum malaria: a secondary analysis of the Transfusion and Treatment of African Children Trial (TRACT). The Lancet Child and Adolescent Health, 2022, 6, 606-613.	5.6	9
65	Once vs twice-daily abacavir and lamivudine in African children. Aids, 2016, 30, 1761-1770.	2.2	8
66	Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys. International Health, 2017, 9, 91-99.	2.0	8
67	Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study. Clinical Infectious Diseases, 2019, 70, 404-415.	5.8	8
68	Comparison of Lymphocyte Subset Populations in Children From South Africa, US and Europe. Frontiers in Pediatrics, 2020, 8, 406.	1.9	8
69	Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis. Journal of the International AIDS Society, 2022, 25, e25871.	3.0	8
70	Whole blood versus red cell concentrates for children with severe anaemia: a secondary analysis of the Transfusion and Treatment of African Children (TRACT) trial. The Lancet Global Health, 2022, 10, e360-e368.	6.3	7
71	The cascade of care for children and adolescents with <scp>HIV</scp> in the <scp>UK</scp> and Ireland, 2010 to 2016. Journal of the International AIDS Society, 2019, 22, e25379.	3.0	6
72	Mortality risk over time after early fluid resuscitation in African children. Critical Care, 2019, 23, 377.	5.8	6

**DIANA M GIBB** 

#	Article	IF	CITATIONS
73	Amoxicillin duration and dose for community-acquired pneumonia in children: the CAP-IT factorial non-inferiority RCT. Health Technology Assessment, 2021, 25, 1-72.	2.8	6
74	Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean?. Antiviral Therapy, 2007, 12, 949-56.	1.0	6
75	The impact of viraemia on inflammatory biomarkers and CD4+ cell subpopulations in HIV-infected children in sub-Saharan Africa. Aids, 2021, 35, 1537-1548.	2.2	5
76	Gastroenteritis Rehydration Of children with Severe Acute Malnutrition (GASTROSAM): A Phase II Randomised Controlled trial: Trial Protocol. Wellcome Open Research, 2021, 6, 160.	1.8	4
77	A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in Africa. American Journal of Hematology, 2022, 97, 527-536.	4.1	4
78	Combining factorial and multi-arm multi-stage platform designs to evaluate multiple interventions efficiently. Clinical Trials, 2022, 19, 432-441.	1.6	3
79	Ebola vaccination. Lancet, The, 2015, 386, 2478.	13.7	2
80	Gastroenteritis Aggressive Versus Slow Treatment For Rehydration (GASTRO). A pilot rehydration study for severe dehydration: WHO plan C versus slower rehydration. Wellcome Open Research, 2017, 2, 62.	1.8	2
81	Brief Report: Cessation of Long-Term Cotrimoxazole Prophylaxis in HIV-Infected Children Does Not Alter the Carriage of Antimicrobial Resistance Genes. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 601-605.	2.1	2
82	Sustainable and cost-effective monitoring of patients on ART. The Lancet Global Health, 2014, 2, e4-e5.	6.3	1
83	Marginal structural models for repeated measures where intercept and slope are correlated: An application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy. PLoS ONE, 2020, 15, e0233877.	2.5	0
84	Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial. Wellcome Open Research, 0, 6, 161.	1.8	0
85	Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status. Aids, 2021, 35, 585-594.	2.2	Ο